Traders sold shares of Eli Lilly and Co (NYSE:LLY) on strength during trading on Friday. $40.28 million flowed into the stock on the tick-up and $93.95 million flowed out of the stock on the tick-down, for a money net flow of $53.67 million out of the stock. Of all equities tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.72 for the day and closed at $79.61
A number of equities analysts have weighed in on LLY shares. Morgan Stanley raised their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. JPMorgan Chase & Co. set a $105.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. Bank of America decreased their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and raised their target price for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Finally, Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $93.47.
The stock has a market cap of $87,220.56, a PE ratio of -398.03, a price-to-earnings-growth ratio of 1.48 and a beta of 0.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32.
The company also recently declared a quarterly dividend, which was paid on Friday, March 9th. Investors of record on Thursday, February 15th were given a dividend of $0.5625 per share. The ex-dividend date was Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.83%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is -1,124.94%.
In related news, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald A. Zakrowski sold 860 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Insiders have sold 224,761 shares of company stock valued at $19,708,235 in the last three months. 0.20% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of LLY. Janus Henderson Group PLC grew its position in Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares during the period. Dodge & Cox grew its position in Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the period. Renaissance Technologies LLC grew its position in Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the period. Bank of Montreal Can grew its position in Eli Lilly and by 85.4% in the 4th quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock worth $391,156,000 after purchasing an additional 2,133,606 shares during the period. Finally, Investec Asset Management LTD bought a new stake in Eli Lilly and in the 4th quarter worth approximately $163,570,000. 76.79% of the stock is owned by institutional investors and hedge funds.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.